🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsCardiovascular OutcomesSOUL trial preliminary data — November 2025 Page 2

SOUL trial preliminary data — November 2025

JenMemphis Sun, Mar 16, 2025 at 2:50 AM 51 replies 2,130 viewsPage 2 of 11
SarahChen_PharmD
VIP Member
4,567
22,341
Dec 2023
San Diego, CA
Mar 16, 2025 at 4:10 PM#6
InsuranceTom said:
Read four things before the headline number.

I read this differently from InsuranceTom, on substance rather than tone. I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them. The results probably generalise, and "probably" should be stated as an assumption rather than dropped.

19 22Dr.ObesityLA, NurseKim_ATL, paul_denver and 16 others
Reply Quote Save Share Report
Dr.RaviCardio
VIP Member
2,890
15,678
Jan 2024
New York, NY
Mar 16, 2025 at 9:26 PM#7
JenMemphis said:
I keep finding that the number in the press summary and the number in the paper are not the same number, and the difference is always in the same…

Forest plot interpretation for the the trial evidence meta-analysis: when reading the pooled estimate, pay attention to:

  1. Point estimate (HR/RR/OR) — center of the diamond
  2. Confidence interval width — precision of the estimate
  3. I² statistic — heterogeneity across studies
  4. Individual study weights — are results driven by one large trial?
  5. Prediction interval — range of plausible true effects in future settings

The the trial evidence meta-analysis shows a pooled RR of 0.79 (95% CI 0.66-0.89), I²=37%. This is a robust and consistent effect.

20 23anna.melb_AU, mark_tokyo, hans_munich and 17 others
Reply Quote Save Share Report
Dr.LeslieOBGYN
Member
567
2,567
May 2024
Dallas, TX
Mar 17, 2025 at 2:42 AM#8
SarahChen_PharmD said:
I would add the less popular caveat: these trial populations under-represented several groups, older adults and the highest BMI categories among them.

Bayesian meta-analysis perspective on the trial evidence: traditional frequentist meta-analyses report point estimates and confidence intervals. Bayesian approaches provide probability distributions that are more intuitive for clinical decision-making.

For example: "There is a 98.5% probability that semaglutide 2.4mg produces >10% weight loss vs placebo" is more actionable than "RR 3.4, 95% CI 2.8-4.1, p<0.001."

The the trial evidence evidence is strong under both frameworks, but Bayesian analysis better communicates the degree of certainty for individual patient counseling.

21 24james_edin, FranDenver, Dr.BariatricHTX and 18 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
DerekSJ_a1c
Member
378
1,678
Aug 2024
San Jose, CA
Mar 17, 2025 at 7:58 AM#9

A narrower follow-up, since the general answer is now clear:

How would you tell the difference between that and the alternative explanation?

Last edited: Mar 17, 2025 at 12:58 PM
22 0traveltech_sara, AttorneyGrant, DebRD_ATL and 19 others
Reply Quote Save Share Report
JenMemphis
Member
267
1,234
Jan 2025
Memphis, TN
Mar 18, 2025 at 9:12 AM#10

Reporting back.

Follow-up: I read the paper rather than the summary and the qualifier I was missing was in the second paragraph of the results.

Last edited: Mar 18, 2025 at 2:12 PM
22 20LarryQC_SD, wanda_boise, NurseAsh_DET and 19 others
Reply Quote Save Share Report

Similar Threads

SELECT trial: 20% MACE reduction — mechanistic deep dive7 replies
Semaglutide cardiovascular benefit independent of weight loss11 replies
STEP-HFpEF: semaglutide in heart failure with preserved EF15 replies
GLP-1 and arterial inflammation — hsCRP and IL-6 reduction data18 replies
Lp(a) on GLP-1 agonists — any impact on this risk factor?8 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register